
    
      The study was stopped at interim analysis in August 2011, as stopping criteria for futility
      were met. There was no statistically significant change on the primary efficacy scale in
      favor of the drug. There was a very small chance that any additional data could change the
      study overall outcome. There were no concerns regarding subject safety.
    
  